YU-YUN SHAOZHONG-ZHE LINPO-CHIN LIANGYU-WEN TIENANN-LII CHENG2021-09-012021-09-012009https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650083184&partnerID=40&md5=50f7a6348add00d04c5342cb205cef22https://scholars.lib.ntu.edu.tw/handle/123456789/580325Bowel perforation is a rare but life-threatening complication of bevacizumab, a new anticancer treatment. Patients with bowel perforation usually present with acute abdominal symptoms. Here a case history is presented to highlight a pancreatic cancer patient on bevacizumab chemotherapy who developed empyema as the first manifestation of gastric perforation. This unusual presentation warns physicians that bevacizumab-related bowel perforation can arise as a thoracic complication, without typical gastrointestinal manifestations, in an advanced cancer patient.[SDGs]SDG3antineoplastic agent; bevacizumab; cefepime; cetuximab; adult; advanced cancer; article; cancer patient; cancer therapy; case report; clinical feature; computer assisted tomography; dyspnea; empyema; fever; human; male; pancreas abscess; pancreas cancer; priority journal; stomach perforation; thorax radiography; Antibodies, Monoclonal; Antineoplastic Agents; Empyema; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computedjournal article194433832-s2.0-67650083184